These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23076821)

  • 21. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial.
    Penack O; Schwartz S; Martus P; Reinwald M; Schmidt-Hieber M; Thiel E; Blau IW
    Ann Oncol; 2006 Aug; 17(8):1306-12. PubMed ID: 16766594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose amphotericin B lipid complex for the treatment of persistent fever of unknown origin in patients with hematologic malignancies and prolonged neutropenia.
    Martino R; Subirá M; Domingo-Albós A; Sureda A; Brunet S; Sierra J
    Chemotherapy; 1999; 45(3):205-12. PubMed ID: 10224343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized comparative trial evaluating the safety and efficacy of liposomal amphotericin B (Fungisome) versus conventional amphotericin B in the empirical treatment of febrile neutropenia in India.
    Jadhav MP; Shinde VM; Chandrakala S; Jijina F; Menon H; Arora B; Kurkure PA; Parikh PM; Kshirsagar NA
    Indian J Cancer; 2012; 49(1):107-13. PubMed ID: 22842177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
    Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
    N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia].
    Badia X; Roset M; Carreras E; Ausin I; Herrera L
    Med Clin (Barc); 2004 May; 122(16):610-6. PubMed ID: 15142508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-benefit assessment of antifungal prophylaxis with liposomal amphotericin B in neutropenic patients.
    Penack O; Reinhold T; Thiel E; Blau IW
    Onkologie; 2007 Dec; 30(12):621-6. PubMed ID: 18063874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M; Letscher-Bru V; Herbrecht R
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
    Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
    Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
    Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and Safety of Low-dose Amphotericin B in Different Antifungal Strategies for Treatment of Invasive Fungal Disease in Patients with Hematological Malignancies].
    Yang L; Jin XS; Li JH; Liu J; Guan W; Gao HH; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):221-225. PubMed ID: 28245405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.
    Azoulay E; Timsit JF; Lautrette A; Legriel S; Max A; Ruckly S; Misset B; Cohen Y; Wolff M
    PLoS One; 2017; 12(5):e0177093. PubMed ID: 28531175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
    Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S
    Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
    Cannon JP; Garey KW; Danziger LH
    Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children.
    Sunakawa K; Tsukimoto I; Tsunematsu Y; Honda M; Iwai N; Maniwa T; Haigo H; Suzuki K; Mori T
    J Infect Chemother; 2012 Aug; 18(4):456-65. PubMed ID: 22286407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A real-world prospective observational study on the efficacy and safety of liposomal amphotericin B in 426 patients with persistent neutropenia and fever.
    Yoshida M; Tamura K; Masaoka T; Nakajo E
    J Infect Chemother; 2021 Feb; 27(2):277-283. PubMed ID: 33109439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies.
    Goto N; Hara T; Tsurumi H; Ogawa K; Kitagawa J; Kanemura N; Kasahara S; Yamada T; Shimizu M; Nakamura M; Matsuura K; Moriwaki H
    Am J Hematol; 2010 Nov; 85(11):872-6. PubMed ID: 20882524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever.
    Ellis M; Bernsen R; Ali-Zadeh H; Kristensen J; Hedström U; Poughias L; Bresnik M; Al-Essa A; A Stevens D
    J Med Microbiol; 2009 Nov; 58(Pt 11):1474-1485. PubMed ID: 19589901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.